Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Yuekang Pharmaceutical: Subsidiary YKYY018's clinical approval for indications of inhalation aerosol therapy for the treatment and prevention of human parainfluenza virus infection
Recently, Yuekang Pharmaceutical issued an announcement stating that its wholly owned subsidiary, Beijing Yuekang Kerui Medical Technology Co., Ltd., has received a Notice of Approval for a drug clinical trial for its YKYY018 nebulized inhalation solution, approving the product to conduct clinical trials for the prevention and treatment of human parainfluenza virus infection.
YKYY018 nebulized inhalation solution is an internationally original fusion inhibition drug independently developed by the company based on its full-process AI platform. It has already received approval from the U.S. Food and Drug Administration and the National Medical Products Administration for clinical trials aimed at preventing and treating respiratory syncytial virus infection.
As of now, there are no approved drugs or vaccines for the treatment of human parainfluenza virus infection worldwide, and there is a significant and urgent unmet need in the fields of clinical treatment and prevention.
(Yuekang Pharmaceutical announcement)
(Editor: Yang Yan Lin Chen)
Key words: